Advertisement

Analysis and treatment of 45 platinum-allergic gynecologic malignant tumors

  • Xiaolin Ma
  • Xiuqin Li
Original Article
  • 18 Downloads

Abstract

Background

This study aimed to explore the potential risk factors of platinum allergy and follow-up treatment to provide a reference for the clinical prevention and treatment of platinum allergic reactions in patients with gynecological tumors.

Methods

The study retrospectively analyzed 45 cases of platinum allergic reactions that occurred in Shengjing Hospital affiliated to China Medical University from August 2010 to July 2016. Analysis of risk factors included the cumulative dose, treatment course and time intervals.

Results

The cumulative carboplatin dose in allergic patients ranged from 900 to 10250 mg (average 4845 mg). The 45 allergic reactions occurred between the 3rd and 25th course of treatment (average 11.4 courses). The average re-treatment interval of carboplatin-allergic patients was 28.1 months, including 93.3% of patients with platinum re-treatment interval of more than 1 year. The allergic reaction occurred in the 2nd or 3rd course of re-treatment in 26 patients, accounting for 70.3% of all patients with recurrence. Seventeen patients were subjected to desensitization therapy, among which 13 cases were well tolerated.

Conclusions

Patients who received more than 8 courses of carboplatin or a cumulative dose of more than 3500 mg were the high-risk population for platinum allergy. The 2nd and 3rd treatment course after restarting carboplatin treatment after an interval time of more than 1 year was the high incident period of carboplatin allergy. Skin tests should be conducted in patients with high risk of carboplatin allergy. In cases of carboplatin allergy, patients could receive carboplatin or oxaliplatin desensitization therapy.

Keywords

Platinum allergy Gynecologic malignant tumors Desensitization therapy High-risk scoring standard 

Notes

Acknowledgements

We thank the physicians, nurses, patients and their families.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Morgan JS, Adams M, Mason MD (1994) Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer 30A(8):1205–1206CrossRefPubMedGoogle Scholar
  2. 2.
    Markman M, Kennedy A, Webster K et al (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17(4):1141–1145CrossRefPubMedGoogle Scholar
  3. 3.
    Hendrick AM, Simmons D, Cantwell BM (1992) Allergic reactions to carboplatin. Ann Oncol 3(3):239–240CrossRefPubMedGoogle Scholar
  4. 4.
    Koren C, Yerushalmi R, Katz A et al (2002) Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol 25(6):625–626CrossRefPubMedGoogle Scholar
  5. 5.
    Bautista MA, Stevens WT, Chen CS et al (2010) Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol 3:12.  https://doi.org/10.1186/1756-8722-3-12 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Shibata Y, Ariyama H, Baba E et al (2009) Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. Int J Clin Oncol 14(5):397–401CrossRefPubMedGoogle Scholar
  7. 7.
    Mariana C, Nichole M, David E et al (2008) Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122(3):574–580CrossRefGoogle Scholar
  8. 8.
    Williams CJ, Whitehouse JM (1979) Cis-platinum: a new anticancer agent. Br Med J 1(6179):1689–1691CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Keys HM, Bundy BN, Stehman FB et al (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340(15):1154–1161CrossRefPubMedGoogle Scholar
  10. 10.
    Morris M, Eifel PJ, Lu J et al (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340(15):1137–1143CrossRefPubMedGoogle Scholar
  11. 11.
    Peters WA, Liu PY, Barrett RJ et al (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18(8):1606–1613CrossRefPubMedGoogle Scholar
  12. 12.
    Whitney CW, Sause W, Bundy BN et al (1999) Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17(5):1339–1348CrossRefPubMedGoogle Scholar
  13. 13.
    Rose PG, Bundy BN, Watkins EB et al (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340(15):1144–1153CrossRefPubMedGoogle Scholar
  14. 14.
    Alberts DS, Canetta R, Mason-Liddil N (1990) Carboplatin in the first-line chemotherapy of ovarian cancer. Semin Oncol 17(1 Suppl 2):S54–S60Google Scholar
  15. 15.
    Viswanathan AN, Moughan J, Miller BE et al (2015) NRG Oncology/RTOG 0921: a phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer 121(13):2156–2163CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Yang L, Guo J, Shen Y et al (2015) Clinical efficacy and safety of paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer. Int J Clin Exp Med 8(8):13690–13698PubMedPubMedCentralGoogle Scholar
  17. 17.
    Symonds RP, Gourley C, Davidson S et al (2015) Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol 16(15):1515–1524CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Souglakos J, Syrigos K, Potamianou A et al (2004) Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Ann Oncol 15(8):1204–1209CrossRefPubMedGoogle Scholar
  19. 19.
    Giacchetti S, Perpoint B, Zidani R et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil–leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136–147CrossRefPubMedGoogle Scholar
  20. 20.
    Lee KH, Kim MK, Kim YH et al (2009) Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study. Cancer Chemother Pharmacol 64(2):317–325CrossRefPubMedGoogle Scholar
  21. 21.
    Chollet P, Bensmaïne MA, Brienza S et al (1996) Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7(10):1065–1070CrossRefPubMedGoogle Scholar
  22. 22.
    Bogliolo S, Cassani C, Gardella B et al (2015) Oxaliplatin for the treatment of ovarian cancer. Expert Opin Investig Drugs 24(9):1275–1286CrossRefPubMedGoogle Scholar
  23. 23.
    Zhang G, Li XP, Liu BJ et al (2013) Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center. Chin Med J (Engl) 126(23):4477–4482Google Scholar
  24. 24.
    Vici P, Sergi D, Pizzuti L et al (2013) Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. J Exp Clin Cancer Res 32(1):49.  https://doi.org/10.1186/1756-9966-32-49 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Markman M, Zanotti K, Kulp B et al (2003) Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Gynecol Oncol 89(3):514–516CrossRefPubMedGoogle Scholar
  26. 26.
    Koshiba H, Hosokawa K, Kudo A et al (2009) Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. Int J Gynecol Cancer 19(3):460–465CrossRefPubMedGoogle Scholar
  27. 27.
    Wang HB, Shen K, Yang JX et al (2009) [Clinical analysis of thirteen cases of hypersensitivity reactions to carboplatin]. Zhonghua Fu Chan Ke Za Zhi 44(11):837–840 (Chinese) PubMedGoogle Scholar
  28. 28.
    Schwartz JR, Bandera C, Bradley A et al (2007) Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants’ Hospital. Gynecol Oncol 105(1):81–83CrossRefPubMedGoogle Scholar
  29. 29.
    Gadducci A, Tana R, Teti G et al (2008) Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 18(4):615–620CrossRefPubMedGoogle Scholar
  30. 30.
    Lee CW, Matulonis UA, Castells MC (2004) Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 95(2):370–376CrossRefPubMedGoogle Scholar
  31. 31.
    Confino-Cohen R, Fishman A, Altaras M et al (2005) Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer 104(3):640–643CrossRefPubMedGoogle Scholar
  32. 32.
    Choi J, Harnett P, Fulcher DA (2004) Carboplatin desensitization. Ann Allergy Asthma Immunol 93(2):137–141CrossRefPubMedGoogle Scholar
  33. 33.
    Rose PG, Metz C, Link N (2014) Desensitization with oxaliplatin in patients intolerant of carboplatin desensitization. Int J Gynecol Cancer 24(9):1603–1606CrossRefPubMedGoogle Scholar
  34. 34.
    Kolomeyevskaya NV, Lele SB, Miller A et al (2015) Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin. Int J Gynecol Cancer 25(1):42–48CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Caiado J, Venemalm L, Pereira-Santos MC et al (2013) Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract 1(5):494–500CrossRefPubMedGoogle Scholar
  36. 36.
    Gomez R, Harter P, Lück HJ et al (2009) Carboplatin hypersensitivity: dose introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. Int J Gynecol Cancer 19(7):1284–1287CrossRefPubMedGoogle Scholar
  37. 37.
    Hesterberg PE, Banerji A, Oren E et al (2009) Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 123(6):1262–1267.e1CrossRefPubMedGoogle Scholar
  38. 38.
    Iwamoto T, Yuta A, Tabata T et al (2012) Evaluation of basophil CD203c as a predictor of carboplatin-related hypersensitivity reaction in patients with gynecologic cancer. Biol Pharm Bull 35(9):1487–1495CrossRefPubMedGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2018

Authors and Affiliations

  1. 1.Department of Gynecology and ObstetricsShengjing Hospital Affiliated to China Medical UniversityShenyangChina

Personalised recommendations